Objective-A comparison ofthe efficacy of verapamil, sotalol, and flecainide to suppress right ventricular tachycardia (VT) in patients with a clinically normal heart.
Abstract
Objective-A comparison ofthe efficacy of verapamil, sotalol, and flecainide to suppress right ventricular tachycardia (VT) in patients with a clinically normal heart.
Design-Patients underwent treatment serially with verapamil (360 mg daily), sotalol (240 or 320 mg daily), and flecainide (200 or 300 mg daily), (the larger dose was for patients heavier than 80 kg) to suppress tachycardia. Each drug was given orally for five half lives before testing.
Patients-23 patients with right VT associated with a clinically normal heart were studied.
Outcome measures-The effects of drug treatment were examined by the number of ventricular events on 24 hour Holter monitoring, and the ability of tachycardia to be induced by treadmill exercise testing (Bruce protocol) and programmed ventricular stimulation (Wellens protocol) , compared with drug free baseline tests.
Setting-Patients were studied in a tertiary referral centre.
Results-All three drugs suppressed ventricular salvos ( > 3, < 5 consecutive ventricular premature contractions) (p < 0-01) and VT (p < 0 05) on Holter monitoring and did not differ statistically in efLect. Exercise induced VT was also suppressed by all three drugs (p < 0-01), and of these sotalo: was the most effective although this was not statistically significant (14/ Conclusions-Ventricular tachycardia associated with a clinically normal heart can be suppressed by flecainide, sotalol, or verapamil. In individual patients sotalol was the most frequently effective drug (effective in > 89% of patients) and is a suitable choice for first line treatment.
(Br Heart J 1992;68:392-7)
Most patients presenting with ventricular tachycardia (VT) have easily detectable underlying cardiac disease, such as coronary artery disease, cardiomyopathy, and valvar or congenital heart disease. Five to 10 percent of patients, however, are reported to have no underlying heart disease as suggested by noninvasive and invasive assessment of left ventricular function and coronary anatomy.`-3
These patients do, however, exhibit variable degrees of histological abnormality on cardiac biopsy (60-90%), including interstitial and perivascular fibrosis and vascular sclerosis, acute or subacute myocarditis, and an increase in interstitial adipose tissue.' The reports on the prognosis of such patients are contradictory.7' Although most authors suggest that prognosis is good, there are several who indicate that this may be a more common cause of sudden death in young patients than previously proposed. '12 Even though treatment may not be indicated on prognostic grounds, many of these patients are severely symptomatic and require treatment to control the tachycardia. Most of the treatment data on these patients consist of short case series and anecdotal reports,'1'5 and there has been no adequate study of the efficacy of antiarrhythmic drugs in controlling this form of VT. Our study examines and compares the efficacy of flecainide, sotalol, and verapamil in the treatment of VT in patients with apparently normal hearts.
Patients and methods

PATIENTS
Twenty three patients with a clinical history of sustained VT (> 30 s) and a clinically normal heart were studied. These patients came from a group of 26 consecutive patients with right ventricular tachycardia seen at our institution over two years. Two patients had had at least two of the drugs used in this study on a previous occasion and these were clinically ineffective. One patient was on amiodarone.
Efficacy offlecainide, sotalol and verapamil in the treatment of right ventricular tachycardia in patients without overt cardiac abnormality These patients were excluded from our study. Patients gave informed consent to the protocol for drug testing and were enrolled in the study on the basis of the following criteria: (a) patients had no history of ischaemic heart disease or congenital cardiac abnormality. 
Statistical analysis
Statistical analysis was performed with the SPSS package (SPSS Inc, Chicago, USA). Inducibility of the tachycardia was assessed when drug free and on each of the drug treatments for each patient. Differences between the results when drug free and during treatment with the three drugs were compared by analyses of variance, contingency tables, and non-parametric analyses as appropriate.
Results
Twenty three patients (12 men) mean age 42 6 (SD 11 8; range 21-69) years were studied. All patients had right VT of which 11 had a rightward axis, four had a leftward axis, and eight had a normal axis. The mean (SD) doses ofthe drugs given were 233 (64 3) mg flecainide, 270 (48 2) mg sotalol, and 360 (0 0) mg verapamil. the end of the test on sotalol did not differ significantly from the other treatments although it was a little lower. Fourteen patients developed exercise induced VT when drug free and in four the arrhythmia was sustained. All three drugs resulted in some suppression of exercise induced VT and there were only two episodes of sustained tachycardia, one on sotalol and one on verapamil. Two patients on flecainide, one patient on sotalol, and three patients on verapamil had VT at exercise on the drug when there had been no arrhythmia when drug free (table 3) . This may be due to the inherent variability of induction of arrhythmia with exercise or a genuine proarrhythmic effect. Sotalol was the best of the three drugs but this difference was not significant (p = 0 4). The stage at which tachycardia was induced was not significantly influenced by the treatments (p = 0 4 for all treatments), though more patients had tachycardia during the test rather than in recovery on flecainide and verapamil when compared with sotalol. Tachycardia was induced by programmed ventricular stimulation in 17 patients when drug free, in all cases only tachycardia that was of similar configuration and axis to the clinical tachycardia was considered relevant. In one patient the clinical tachycardia was only stimulated after isoprenaline infusion (2 ig/ min) when drug free and the same dose of isoprenaline was used on all the subsequent trials with antiarrhythmic treatment. In seven patients, the induced tachycardia was sustained. Inducible tachycardia was rendered non-inducible by all three drug treatments in over 50% of the patients ( tFor differences between the drug treatments and drug free for induction of ventricular tachycardia (VT).
and non-sustained (2/7 v 6/7) these differences were not significant (p = 0 4 and p = 0-9).
More patients were inducible (6/17) and sustained (4/7) on verapamil when compared with sotalol (p = 0 07 and p = 0-8 respectively). If the induction and suppression of only sustained VT was considered, the results were similar and all three drugs suppressed inducible VT, but did not achieve statistical significance because of the small numbers. The stage of the Wellens protocol at which tachycardia was induced was also increased by all three treatments (p < 0-01) but no difference could be shown between the treatments (p = 0 4; data not presented). Two patients on flecainide, one patient on sotalol, and three patients on verapamil developed sustained VT on the drug, whereas VT in these patients had been non-sustained when drug free. In one patient the induced tachycardia was faster on sotalol than the drug free arrhythmia and required cardioversion, whereas two of the tachycardias induced on verapamil were haemodynamically unstable, requiring cardioversion. Side effects from the drugs included five patients who experienced dizziness on flecainide and six said they were tired on sotalol. Two patients had some tiredness on verapamil. Individual patients responding to one drug, in general responded to the other drugs and there was no difference in the efficacy of the drugs in patients with abnormal histology compared with those with normal histology in any of the three tests.
Discussion
The results suggest that right VT associated with a normal heart responds well to the drugs tested in this study. Although differences between the drugs did not achieve significance, sotalol was generally the most effective. Earlier studies of the treatment effects of drugs in VT associated with a normal heart are few. Buxton Our study is not a randomised controlled trial, and therefore, it is difficult to ascertain placebo effects, elements of bias, and carry over effects. Although it is straightforward to organise and conduct a study oftwo drugs in a double blind placebo controlled manner, a trial involving three drugs and a placebo presents considerable logistic difficulties. The study does not include drug concentrations and although sotalol and flecainide have somewhat long half lives, that of verapamil is variable. Furthermore, verapamil is subject to substantial first pass metabolism. To minimise variation due to these factors, exercise tests and programmed stimulation were performed two to four hours after the last drug dose. The tests used for evaluation of drug efficacy in this study are not subject to bias, and adequate periods were allowed for the drug concentrations to equilibrate and wash out. This study, despite its deficiencies, is the only systematic study of drug efficacy in the suppression of VT associated with a normal heart. A study of this nature does, therefore, provide valuable information allowing appropriate choice of drug for patients with this form of tachycardia.
All patients had left bundle branch blocklike morphology VT, which can usually be mapped to the right ventricle3 and is often from the region of the outflow tract when associated with a rightward or normal axis. Electrophysiological mapping of the tachycardia of patients in this study was performed in eight cases and this showed the origin of the tachycardia to be in the right ventricle or the septal aspect of the right ventricular outflow tract in seven subjects and in the free wall ofthe outflow tract in one. Our experience with these forms of tachycardia is similar to that of other groups in that they are often inducible by exercise and less frequently by programmed ventricular stimulation.79
Whether this form of tachycardia requires treatment, and the prognosis of VT associated with a normal heart remain controversial issues. Many studies suggest that when VT occurs in association with a normal heart prognosis is good and the patients do not suffer sudden death.278 This contrasts with VT associated with ischaemic heart disease and cardiomyopathy where there is a high mortality associated with symptomatic VT. There are, however, several studies reporting that prognosis of VT in young patients with "normal" hearts may be worse than previously proposed.' ' 
